Section 1 Reauthorization of grants and contracts for development of orphan drugs
Section 5(c) of the Orphan Drug Act (21 U.S.C. 360ee(c)) is amended by striking “2018 through 2022” and inserting “2023 through 2027”.
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”).
A BILL
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as orphan drugs).